All I can think of is how dumb MEDX board was to sell out for $2.1B!
They might have been dumb, but I don’t think it’s fair to say this just because Ipi succeeded in melanoma. This was a relatively high-risk program even within the confines of oncology.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”